Cerulean appoints Edward Garney CMO
This article was originally published in Scrip
Executive Summary
Cerulean Pharma, a developer of tumour-targeted nanopharmaceuticals, has appointed Dr Edward Garney chief medical officer. Dr Garney previously served as vice-president for clinical development at ArQule, where he developed and oversaw clinical trials of its lead non-small cell lung cancer treatment, ARQ 197 (tivantinib).